GlassScriptPhysician profile
Aditya Bagrodia
NPI 1730310665
$49,336.24
in general payments reported to CMS, 2019-2025
38 companies · $18K in 2025
The $18K reported for 2025 was more than what 96% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $801 · 2020: $1,421 · 2021: $470 · 2022: $1,427 · 2023: $944 · 2024: $26K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Honoraria: $10K · Food and Beverage: $3,690 · Travel and Lodging: $3,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,325.00 |
| Honoraria | $10,187.50 |
| Food and Beverage | $3,689.75 |
| Travel and Lodging | $3,014.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $31,747.24 | 2024-2025 | Adstiladrin |
| Urogen Pharma, INC. | $10,764.97 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $877.19 | 2020-2025 | Lynparza |
| Ethicon US, LLC | $713.68 | 2020-2025 | Surgiflo Hemostatic Matrix, Echelon Flex, Echelon; Endopath |
| Intuitive Surgical, INC. | $620.39 | 2019-2025 | |
| Medtronic, INC. | $537.40 | 2022-2024 | Interstim |
| Bayer Healthcare Pharmaceuticals INC. | $441.82 | 2020 | |
| Photocure INC | $345.47 | 2019-2025 | Cysview |
| Teleflex LLC | $226.10 | 2024 | |
| Janssen Biotech, INC. | $217.66 | 2022-2025 | Erleada |
| Merck Sharp & Dohme LLC | $190.77 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Foundation Medicine, INC. | $176.72 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $173.06 | 2024-2025 | Erleada |
| Conmed Corporation | $156.84 | 2020 | |
| Davol INC. | $155.46 | 2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $146.62 | 2023 | |
| Boston Scientific Corporation | $142.84 | 2022 | |
| Exelixis INC. | $134.34 | 2022-2025 | Cabometyx |
| Profound Medical Corp. | $129.21 | 2024-2025 | Tulsa-Pro |
| Sumitomo Pharma America, INC. | $125.00 | 2025 | Orgovyx |
| Olympus America INC. | $115.39 | 2019 | |
| Blue Earth Diagnostics | $115.12 | 2022-2025 | Posluma |
| Ambu INC. | $114.34 | 2022 | |
| Dendreon Pharmaceuticals LLC | $113.95 | 2019 | |
| Procept Biorobotics Corporation | $108.52 | 2021 | |
| Medtronic USA, INC. | $97.79 | 2020 | |
| Karl Storz Endoscopy-America | $88.19 | 2019 | |
| Histosonics, INC. | $79.01 | 2024 | |
| Coloplast Corp | $77.64 | 2024-2025 | |
| Edap Technomed INC | $76.68 | 2022-2023 | |
| Astellas Pharma US INC | $72.41 | 2019 | |
| Eisai INC. | $61.82 | 2023-2024 | |
| Pfizer INC. | $50.49 | 2019-2024 | |
| Immunitybio, INC. | $46.21 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $35.66 | 2023 | Myrisk |
| Novartis Pharmaceuticals Corporation | $22.41 | 2022 | |
| Integra Lifesciences Corporation | $21.40 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Antares Pharma, INC. | $16.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aditya Bagrodia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.